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Abstract
Background: Inter-patient variability in response to opioids is well known but a comprehensive definition of its
pathophysiological mechanism is still lacking and, more importantly, no studies have focused on children. The STOP
Pain project aimed to evaluate the risk factors that contribute to clinical response and adverse drug reactions to
opioids by means of a systematic review and a clinical investigation on paediatric oncological patients.
Methods: We conducted a systematic literature search in EMBASE and PubMed up to the 24th of November 2016
following Cochrane Handbook and PRISMA guidelines. Two independent reviewers screened titles and abstracts
along with full-text papers; disagreements were resolved by discussion with two other independent reviewers. We
used a data extraction form to provide details of the included studies, and conducted quality assessment using the
Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
Results: Young age, lung or gastrointestinal cancer, neuropathic or breakthrough pain and anxiety or sleep
disturbance were associated to a worse response to opioid analgesia. No clear association was identified in
literature regarding gender, ethnicity, weight, presence of metastases, biochemical or hematological factors. Studies
in children were lacking. Between June 2011 and April 2014, the Italian STOP Pain project enrolled 87 paediatric
cancer patients under treatment with opioids (morphine, codeine, oxycodone, fentanyl and tramadol).
Conclusions: Future studies on cancer pain should be designed with consideration for the highlighted factors to
enhance our understanding of opioid non-response and safety. Studies in children are mandatory.
Trial registration: CRD42017057740.
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Background
Worldwide incidence of childhood cancer is about 160,000
new cases/year with 90,000 deaths/year under 15 years of
age [1]. Young people with cancer experience multiple symp-
toms which negatively affect their quality of life [2]. Children
with cancer often report pain (up to 89% of patients in an
advanced stage of the disease) and over 70% of them some-
times report severe pain [3, 4]. Even though pain relief is one
of the main concerns of physicians [5] and the inter-patient
variability in response to opioids is well known [6], pain relief
is still often misdiagnosed or treated inappropriately. In
adults, current evidence suggests that several factors may in-
fluence analgesic response during the course of the illness
[7]. For example, it has been reported that men require more
morphine in the postoperative period than women [8] and
obesity may partly explain inter-individual variations in opi-
oid efficacy and toxicity [9]. Moreover, it is fundamental to
consider the influence of genetic factors regulating opioid
pharmacokinetics (e.g. UDP-glucuronosyltransferase genes,
UGT) [10] and pharmacodynamics (e.g. μ-opioid receptor
gene, OPRM1) [11] on opioid response variability. In this
frame, the region of Tuscany (Italy) developed a research
program (“Pharmacogenetics in pain therapy”) in 2006 to
evaluate the association between single nucleotide polymor-
phisms (SNPs) in metabolizing genes and the response to
opioids in a general population. To the best of our know-
ledge, no similar epidemiological and genetic study has yet
been conducted to address these important issues in paediat-
ric populations even if physiological differences between
adults and children are well known [12]. Furthermore, chil-
dren experience illnesses and are subjected to medical care
differently from adults and they depend on their parents to
cope with stressful situations [13]. Therefore, familiar context
may be an influencing factor on the perception of pain and
the efficacy of pain therapy.
For these reasons, in 2010 we designed a longitudinal study
focused only on paediatric cancer patients, called STOP Pain
(Suitable Treatment for Oncologic Paediatric Pain) to con-
tinue recruitment for the regional study in an attempt to get
as homogeneous a sample as possible, i.e. patients from the
same population (with cancer pain) and treated in a homoge-
neous way. The main objectives of the project are to conduct
a comprehensive literature review of the association between
inter-individual opioid responsiveness, socio-demographic
and medical factors and to evaluate the risk factors that con-
tribute to response/non-response and adverse drug reactions
to opioids in a sample of paediatric oncological patients.
Methods
Systematic review of current literature
This review was performed in accordance with the Cochrane
Handbook and the Prisma Statement for Systematic Reviews
[14] and it was registered in PROSPERO with the number
CRD42017057740 [15].
A systematic PUBMED and EMBASE search for any
study evaluating opioid non-response and safety among
cancer patients was performed up to the 24th of November
2016. Four themes (drugs, cancer, randomized clinical
trials, and observational studies) were combined by using
the Boolean operator “and” (see full search strategy in
Additional file 1). We took into consideration articles
(excluding letters) published in English and Italian, and
studies on humans using the corresponding filters. We also
searched the papers among those quoted as references in
the retrieved studies, as well as in a few previous reviews.
Two investigators (AP and GC) independently reviewed
titles and abstracts, and selected articles. Any disagree-
ments was resolved through discussion and consensus with
two other independent reviewers (EL and VM).
In a second phase, we retrieved the full texts and selected
the original articles based on the following criteria:
1) Patients included were cancer patients
2) Drugs involved were opioids
3) Outcomes evaluated were opioid non-response and
safety (see Additional file 2)
4) One or more variables were studied as factors
associated to therapy outcome
We decided not to consider putative genetic factors since
a large body of evidence was already available. Moreover,
we excluded pharmacokinetic studies as well as clinical
trials and comparative studies evaluating different drugs,
drug doses, formulations and administration routes.
For each retrieved study, we extracted the following
data: location, year of publication, study type, size, mean
age and gender of the sample, tumor characteristics,
drugs used and main findings.
The quality of the included studies was assessed using
the “Quality Assessment Tool for Observational Cohort
and Cross-Sectional Studies” [16] following the criteria
reported in Additional file 3.
STOP pain project
The study enrolled paediatric patients receiving opioids
(morphine, codeine, oxycodone, fentanyl and tramadol)
for cancer-related pain relief between June 2011 and
April 2014. The institutional review board of Meyer
Children’s Hospital approved the study.
Two structured questionnaires were administered to the
enrolled children or their parents after obtaining written in-
formed consent. The first questionnaire included demo-
graphic information (e.g. age, gender, weight, height, and
allergies), medical history, concomitant illnesses and life-
style of the children. Data concerning cancer diagnosis and
evolution of the disease were collected from medical re-
cords. Data on health conditions as well as other parame-
ters potentially predictive of high or low treatment
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responsiveness were collected carefully with the aim of
adjusting for any confounding variables and/or effect modi-
fiers. The second questionnaire included demographic in-
formation on parents and family environment.
An Individual Case Report Form (CRF) recorded all data.
Unique Patient Code anonymized the patient before the
matching with genetic data. Peripheral blood or mouth
swab (when possible) were collected after patient recruit-
ment. DNA was isolated using EZ1 Extractor (Qiagen) and
standard commercial kits. DNA concentration and purity
was then measured with NanoDrop 2000 (Thermo Scien-
tific) and stored at − 20 °C. Genotyping was carried out
using the Taqman assay (ABI, Applied Biosystems, Foster
City, CA). Taqman probes were designed and synthesized
by Applied Biosystems, who also provided standard PCR
profile and reaction conditions. PCR plates were read on a
7500 Fast Real Time PCR system (Applied Biosystems).
Opioid dosing was standardized through the conversion to
intravenous (IV) morphine equivalents (ME) according to the
following opioid equi-analgesic calculation [17]: IV ME= oral
oxycodone*2/3 = IV tramadol*10 = oral tramadol*30 = oral
codeine *30 = IV fentanyl/100. When the direct conversion
factor to IV ME was not available, the dosage was first con-
verted to oral morphine equivalents and then to IV ME (3:1).
Data are presented as mean and standard deviation.
We considered the following two outcomes regarding
dose: dose (mg/kg) of IV ME administered during the
first 24 h of treatment (Dose24h) and total dose (mg/kg)
of IV ME (Dosetot).
The Visual Analogue Scale (VAS) was compiled by
children of older age (> 6 yrs). Wong & Baker FACES
Pain Rating Scale was administered to children between
4 and 6 years of age as an alternative outcome measure.
When self-reporting of pain was not possible, such as in
children who had difficulty verbalizing the presence or
intensity of pain, the FLACC scale was used. Nurses ad-
ministered the scales for pain intensity to patients at the
first examination, repeating the procedure eight-hourly
for intra-individual pain intensity evaluation.
We considered the following three outcomes regarding
pain intensity: pain intensity before treatment (PIto); differ-
ence between pain intensity after 24 h of treatment and PIto
(Δ VAS); time to reach the lowest possible pain intensity
(Timetot).
Evaluated side effects were gastrointestinal effects
(nausea/vomiting, diarrhea and constipation), central
nervous system effects (agitation, drowsiness, headache
and sedation), and all adverse effects (gastrointestinal
and central nervous system effects, and itching).
We checked data for consistency and completeness by
tabulating the variables of interest. We compared differences
for mean values of continuous response variables by
one-way ANOVA and differences for percentages of categor-
ical variables by chi-square test.
Results
Systematic review
The PUMBED and EMBASE search produced 9847 re-
cords. A review of titles and abstracts resulted in the se-
lection of 336 records of original studies, among which
72 met the inclusion criteria. Figure 1 reports the flow-
chart of study selection.
The characteristics of 74 studies included in this review
[18–91] are reported in Additional file 2. Thirty-three studies
were conducted in Europe, 16 in Asia, 22 in North America,
one in South America (Brazil) and two in Turkey. Eighteen
studies were published before 2000; 61 studies were
conducted on more than 50 patients; two studies were con-
ducted on female patients, two others mainly on males, and
in the remaining studies the proportions of the two genders
were similar. Four studies were conducted on children. The
studies reported a broad variety of opioid non-response out-
comes, and only a few outcomes were evaluated in more
than two trials. In particular, non-response was defined as
high dosage or pain intensity, low pain control or relief,
switching, high Opioid Escalation Index (OEI) percentage, or
worsening of pain. Patients used more than one opioid or
non-specified opioids in 41 studies. Morphine was used
alone in 19 studies, oxycodone alone in six, methadone alone
in three and fentanyl alone in four studies. More than half of
the included studies (41 out of 74) reported the opioid doses
in milligrams of morphine equivalents.
For the included studies, the assessment of methodo-
logical quality was performed (Additional file 4) using the
Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies [16]. Items 1, 4, 6, 7, 9, 10, 11 and
13 have received affirmative responses from 100% of the
studies included in the analysis. More than 50% of studies
clearly defined the population analyzed (item 2) and per-
formed an adjusted statistical analysis for confounding
variables (item 14). Not reported (NR) was the answer to
items 3 and 5 respectively in 58 and 99% of included stud-
ies, while not applicable (NA) was assigned for more than
50% of studies for items 8 and 12.
Given the high number of factors considered, we de-
cided to report only the results on associations investi-
gated in more than three studies and found in 39 studies
including more than 50 subjects and published after
2000 (Table 1). With regard to socio-demographic fac-
tors, while no association was found with age in nine
studies, nine other studies reported an inverse associ-
ation (i.e. older patients had a better response compared
to younger ones) while three found a direct one. Gender
was not related to non-response in 15 studies, two stud-
ies reported that males had a worse response than fe-
males, while one study stated that they had a better one.
Body mass index (BMI) was investigated in two studies
with no notable relationship found, while a direct associ-
ation between non-response and weight gain was
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reported in one study (i.e. patients with high weight had
a worse response compared to low-weight patients). Fi-
nally, two studies reported no association with alcohol-
ism and one a direct association with alcohol abuse (i.e.
subjects who abused alcohol had a worse response com-
pared to those with normal drinking habits).
Cancer diagnosis, biochemical parameters, cognition,
metastases location, psychological distress, and sleep
disturbances were the clinical factors studied, with high
heterogeneity of specific measures investigated and no
clear association with outcomes. However, patients with
lung cancer or mesothelioma (three out of 16 studies) or
gastrointestinal cancer (two studies) had a worse re-
sponse (direct association), as did patients with anxiety
(two studies), or sleep disturbance (two out of four
studies).
Pain-related factors were investigated and two studies
reported a direct association between breakthrough can-
cer pain and worse response (i.e. subjects with break-
through pain had a worse response), while one study
reported no association. Similarly, two studies reported a
direct association with incidental pain while two others
found no association.
High heterogeneity emerged for measures of pain in-
tensity and with regard to pain pathophysiology (neuro-
pathic, visceral, somatic, etc.) with no clear association,
although four out of 11 studies reported a direct associ-
ation between the presence of neuropathic pain and opi-
oid non-response.
Finally, analgesic drugs, adjuvants and other drugs
were often studied as possible factors associated with
non-response but contrasting results were reported.
Results on predictive factors of opioid safety are shown
in Table 2.
Compared to younger patients, older ones reported a
lower rate of myoclonus, urinary hesitancy, dry mouth, and
nausea. No notable relationship was found between gender
and itch, myoclonus, nausea, urinary hesitancy and consti-
pation nor between age and anorexia, itch, nausea, consti-
pation, confusion, or drowsiness, whereas anorexia and dry
mouth were more common in female patients and consti-
pation, dry mouth, and hallucinations were more frequent
in older patients in only one study. We found no relation-
ship between most clinical factors (i.e. biochemical parame-
ters, cancer diagnosis and terminal stage) and the
occurrence of adverse events although constipation was re-
lated to low glomerular filtration rate (GFR), comorbidity
and terminal stage, as well as to confusion and drowsiness.
The presence of neuropathic or somatic pain was related to
the onset of confusion and dry mouth; while visceral pain
was associated with a high frequency of dry mouth and
gastrointestinal symptoms.
No significant differences in side effects were observed
regarding anorexia, somnolence, nausea, vomiting, consti-
pation, dry mouth, and emesis despite high opioid doses.
However, an inverse association was found between opioid
dose and dry mouth, while one study reported a direct as-
sociation with urinary hesitancy. One study found a direct
Records identified through 
PUBMED searching
n = 4032
Records identified through 
EMBASE searching 
n = 7990
Records after duplicates removed
n = 9847
Records screened
n = 9847
Records excluded
n = 9511
Full-text articles assessed 
for eligibility
n = 336
Full-text articles excluded, 
with reasons 
n = 262
146 not pertinent
76 case reports
33 letters
7 reviews
Studies included in 
qualitative synthesis
n= 74
Fig. 1 PRISMA Flow diagram
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association between the length of opioid therapy and con-
comitant use of more than two opioids and the onset of
constipation; nevertheless, the association was denied in
another study. A direct relationship was found between
opioid switching, dysuria, and constipation.
Validation of the Prisma checklist for the systematic
review is reported in Additional file 5.
STOP pain project
One hundred twenty-nine (75 + 54) patients met the
inclusion criteria and resulted eligible for the study.
Informed consent was requested from parents of 54
children but they were not included in the study for
the following reasons: refusals (n = 6), terminally ill
patients (n = 9), early discharge (n = 7), hospitalization
in sterile room (n = 7), non-Italian speaking parents
(n = 25).
The data set consisted of the characteristics of 87 pa-
tients enrolled between June 2011 and April 2014. For
seven patients the biological sample was not available.
STAI test was completed by 40 parents (37 mothers).
Table 3 presents the distribution of selected characteris-
tics among 87 cancer patients included in the STOP Pain
Project. The majority of children were male (56.32%) with
more than 3 years of age (36.78% between 3 and 12 years,
42.53% over 12), and a BMI of more than 15 kg/m2
(44.83% between 15 and 20 kg/m2, 25.29% more than 20).
Cancer diagnoses were mainly leukemia and lymphoma
(39.08), sarcoma (20.69%) or osteosarcoma (19.54%), in
26.44% of cases with metastases, with oral cavity (49.43%)
or skeletal (16.09%) pain. Patients were treated with
morphine (68.97%), tramadol (21.84%), oxycodone
(2.30%), codeine (2.30%) and more than one opioid
(4.60%) for the achievement of pain relief. Table 4 shows
the selected outcomes to evaluate opioid responsiveness
of the 87 patients in terms of opioid dosage requirements
and pain intensity assessment.
The aim of the present study was to investigate pa-
tient’s genetic predisposing trait (single nucleotide poly-
morphisms of genes involved in opioid transport, target
and metabolism) to opioid responsiveness and safety
profile. The investigated genes were ABCB1 (ATP bind-
ing cassette subfamily B member 1), COMT (catecho-
l-O-methyltransferase), IL6 and IL8 (interleukin 6 and
8), KCNJ6 (potassium inwardly-rectifying channel, sub-
family J, member 6), NR1I2 (nuclear receptor subfamily
1 group I member 2), OPRM1 (opioid receptor, mu 1),
TNF-α (tumor necrosis factor α) and UGT2B7 (UDP
glucuronosyltransferase 2 family, polypeptide B7). For
SNP selection, high priority was given to those SNPs for
which functional alteration data were available in the lit-
erature and the minor allele frequency is above 15% in
the Caucasian population.
Discussion
Systematic review
The large inter-individual variability in response to opi-
oid analgesia and high prevalence of adverse events asso-
ciated with their use underline the clinical importance of
being able to predict who will or will not respond to opi-
oid treatment.
Patient characteristics
According to our review, opioid non-response is associated
with age in that older patients had a better response
(inverse association). This result can be found in the major-
ity of studies that show that elderly patients present an in-
creased sensitivity to opioids [40]. Indeed, as age increases,
there is a decrease in the volume of distribution and clear-
ance of morphine, as well as a decrease in plasma albu-
min–the latter resulting in a greater unbound fraction of
drug. These pharmacokinetic factors will lead to higher
plasma levels and a longer duration of morphine action in
elderly compared to younger patients receiving the same
dose of the drug. In contrast with the widely reported
sex-related differences in opioid response [92], we found no
influence of gender. In particular, according to literature,
females are more sensitive to morphine than males [93]
while pain perception is reported to increase with the
Table 3 Demographic and clinical characteristics of 87 patients
Number Percent
Gender
Male 49 56.32
Female 38 43.68
Age (months)
0–36 18 20.69
> 36–144 32 36.78
> 144 37 42.53
BMI
< 15 25 28.74
15- < 20 39 44.83
≥ 20 22 25.29
missing 1 1.15
Diagnosis
Brain Tumor 6 6.90
Leukemia and Lymphoma 34 39.08
Neuroblastoma 6 6.90
Osteosarcoma 17 19.54
Sarcoma 18 20.69
Others 6 6.90
Metastasis
No 64 73.56
Yes 23 26.44
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lowering of estrogen levels (such as in menopause) [94],
suggesting that aging might contribute to level the gender
differences in opioid response. This could explain the lack
of association between gender and non-response found in
our review since all included studies enrolled patients over
the age of 60 and did not take into account menopausal
status.
Type of cancer
We also found that patients with lung or gastrointestinal
cancer had a worse response to opioid analgesia (direct as-
sociation). Most surveys on cancer pain have not assessed
the effect of primary diagnosis on the incidence, intensity,
and treatment of cancer pain since the assessment of these
effects is often complicated by the existence of multiple
medical problems. The current evidence emerging mainly
from studies conducted in palliative care units suggests
that somatic pain is associated with lung, head and neck,
breast, and prostate cancer, while visceral pain is associ-
ated with colorectal, gastric, liver, pancreatic, and uterine
cancer [41]. Moreover, primary gastrointestinal and lung
carcinomas, as well as metastatic bone disease, ovarian
carcinoma, and brain tumors are often associated with
high and very high morphine dosages [76].
Psychological factors
Patients with anxiety or sleep disturbance had a worse re-
sponse (direct association). Psychological distress is often
assessed by patients themselves via several health-related
quality of life tools and in particular the EORTC
QLQ-C30 (emotional functioning scale), a test able to as-
sess many psychological parameters, including major de-
pression, anxiety, or hostility that can make treatment
more difficult [75]. Untreated anxiety has a negative im-
pact on the management of cancer pain [95]. Sleep distur-
bances can be generated by anxiety but they might also be
independent, thus more detailed information on sleep
quality through specific sleep questionnaires (e.g. Pitts-
burgh Sleep Quality Index) could add further information
[51].
Pain characteristics
Patients with neuropathic or breakthrough pain had a
worse response (direct association). Breakthrough pain,
including incidental pain, is a transient exacerbation of
pain that occurs either spontaneously or in relation to a
specific predictable or unpredictable trigger [96]. Neuro-
pathic pain is defined as the pain caused by a lesion in
the peripheral or central nervous system resulting from
cancer or other causes such as chemotherapy. Despite
significant progress in cancer research, few data are
available yet on the pathophysiology of neuropathic pain
due to cancer. The management of neuropathic pain is
often inadequate and analgesic therapies need to be sup-
ported by adjuvants, such as anticonvulsants drugs, cor-
ticosteroids and antidepressants [97].
Other drugs
No clear association was found between the use of other
drugs and opioid non-response. The use of nonsteroidal
anti-inflammatory drugs (NSAIDs) and steroids is recom-
mended in combination with weak or low dose opioids.
Table 4 Pain intensity assessment and opioid dosage
requirements of the 87 patients
mean ± SD
PIt0 (Pain Intensity at t0) 4.34 ± 2.17
PI24h (Pain intensity at t24h) 2.04 ± 2.56
PIend (Pain intensity at tend) 1.07 ± 2.19
Timetot (time to the minor PI) 140.43 ± 63.89
N %
PIt0 (grouped)
≤4 47 54.02
> 4 40 45.98
ΔVAS (PIt0 - PIt24h; grouped)
≤ 2 46 52.87
> 2 39 44.83
Responders (PIend equal to 0)
No 23 26.44
Yes 64 73.56
Pain location
Abdominal 12 13.79
Oral cavity 43 49.43
Skeletal - Muscle 14 16.09
Other 18 20.69
Drug
morphine 60 68.97
tramadol 19 21.84
oxycodone 2 2.30
codeine 2 2.30
more than one 4 4.60
Dose24h (mg/kg)
≤ 0.2 24 27.59
0.2-≤ 0.42 20 22.99
0.42-≤ 0.50 22 25.29
> 0.50 19 21.84
Missing 2 2.30
Dosetot (mg/kg)
≤ 1.2 21 24.14
1.2-≤ 2.16 20 22.99
2.16-≤ 3.42 24 27.59
> 3.42 22 25.29
PI Pain Intensity
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Therefore, their usage may be directly linked to
non-response because of poor treatment. On the other
hand, proton pump inhibitors and laxatives might be pre-
scribed to relieve adverse effects induced by high dose opi-
oids. The use of these drugs may enhance response when
concomitantly prescribed with high dose or strong
opioids.
While some preliminary data were available, the rela-
tionship between non-response and cancer site, presence
and location of metastases, and cognition was not defined.
In light of these results, we strongly suggest that future
studies on cancer pain be designed with the specific aim
of enhancing our understanding of opioid non-response
and safety. Further information could be obtained
through individual patient data meta-analysis, however it
could be burdensome per se and problematic due to the
low quality of original papers as well as the heterogen-
eity of the definition of “non-response” reported in the
studies conducted up to now.
Moreover, the use of morphine dose to define drug re-
sponse might be questionable. In our opinion, more efforts
should be made to include proper treatment response eval-
uations, which can assess the real decrease in pain intensity
through use of validated instruments, and not only through
drug dose as a proxy. Further efforts should be made to
precisely and routinely measure cancer pain in the strictest
and most reliable manner available. This issue could be
properly approached by clinicians according to Evidence
Based Medicine parameters and not, as often still happens,
according to their personal beliefs, hospital tradition or to
unreliable self-reporting instruments.
Strengths of this systematic review
 A comprehensive and robust systematic review in
accordance with Cochrane Handbook and PRISMA
guidelines.
 Search of two electronic database and assessment of
the methodological quality of the included studies.
 All reviewing and data extraction was carried out by
one author and double-checked by a second author;
two other independent reviewers discussed and
resolved any disagreement.
 Evaluation of a broad range of risk factors
contributing to clinical response and adverse drug
reactions to opioids.
Limitations of the systematic review
 Definition of “non-response” reported in the studies
included in the systematic review was
heterogeneous.
STOP pain project
In an effort to overcome the above mentioned problems, a
longitudinal, nation-wide, paediatric study was planned by
the Department of Neuroscience, Psychology, Drug Re-
search and Children’s Health of the University of Florence,
Italy and Anna Meyer Children’s University Hospital
(Florence, Italy) entitled “STOP Pain - Suitable Treatment
for Oncologic Paediatric Pain”.
In particular, the study uses more than one outcome to
evaluate opioid responsiveness in terms of both opioid
dosage and pain intensity assessment. This point raises
the challenge of selecting a proper outcome measure of
pain since it is a subjective experience that might be quite
difficult to quantify [98]. In 2010, the AIRC (Italian
Association for Cancer Research) financed this research
program with the aim to evaluate the association between
genetic factors and response to opioids in children. STOP
Pain, comprehensive of the previous literature review, was
a pilot study attempting to propose specific definition of
clinical outcomes and their associated factors in a
homogenous population (i.e. paediatric cancer-related
pain patients). In fact, the main limitation of the study was
the number of enrolled patients even if many of them
were treated in a homogeneous way, i.e. titration of mor-
phine by continuous infusion (60 out of 87).
Moreover, since children suffer from different types of can-
cer pain, the fact we did not characterize the nature of such
pain (i.e. nociceptive, neuropathic, procedural, etc.) could
represent another point of weakness of our study. Neverthe-
less, in some disease conditions, as well as in cancer, patients
may have mixed pain consisting of somatic, visceral and
neuropathic pain all at the same time or each separately at
different times [99]. Clinical distinction between nociceptive
and neuropathic pain is based on the anatomic origin of the
stimulus, which was not clearly identifiable based on clinical
data available for our pediatric patients.
In any case, planning of multicentric studies is pivotal
to reach the appropriate sample size to address multiple
comparison problems and capture minor genetic effects.
Conclusions
It is our hope that the design of larger studies will
consider the factors highlighted in the present work to
enhance the understanding of opioid non-response and
safety. And finally, we wish to underscore the necessity
for studies on children in this field.
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